Published in Eur J Clin Pharmacol on January 01, 1986
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol (1986) 1.25
Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol (1986) 1.23
Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol (1990) 1.13
The pharmacology of tramadol. Drugs (1994) 1.09
Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol (1989) 1.09
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol (1987) 1.03
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol (1993) 0.95
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol (1990) 0.91
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol (1990) 0.90
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol (2003) 0.90
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol (1989) 0.88
Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol (1991) 0.85
The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol (1998) 0.83
Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol (1993) 0.78
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect (1992) 0.76
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988) 3.69
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet (1990) 3.64
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet (1989) 2.90
Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum (2003) 2.51
Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol (1990) 2.31
Intermittent acute porphyria--demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med (1972) 2.17
Parenchymal cells from adult rat liver in nonproliferating monolayer culture. I. Functional studies. J Cell Biol (1973) 2.09
Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther (1988) 1.94
Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A (1991) 1.91
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol (1989) 1.87
Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A (1988) 1.82
Decreased red cell uroporphyrinogen I synthetase activity in intermittent acute porphyria. J Clin Invest (1972) 1.80
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol (1993) 1.79
Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics (1988) 1.75
Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet (1985) 1.70
Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol (1999) 1.63
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet (1991) 1.60
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol (1991) 1.57
Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci U S A (1988) 1.57
Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics (1997) 1.55
Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem (1990) 1.50
Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol (1996) 1.50
Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology (1985) 1.47
Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry (1988) 1.44
Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther (1980) 1.44
Characterisation of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol (1987) 1.42
Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun (1988) 1.42
Primary liver carcinoma in two sisters with acute intermittent porphyria. Am J Med (1990) 1.41
Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J (1993) 1.41
Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol (1991) 1.39
N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits. Proc Natl Acad Sci U S A (1989) 1.39
Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther (1990) 1.37
Drug metabolism in adult rat hepatocytes in primary monolayer culture. Gastroenterology (1977) 1.35
Nucleotide sequence of a full-length cDNA for arylamine N-acetyltransferase from rabbit liver. Nucleic Acids Res (1989) 1.35
Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol (1984) 1.35
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest (1990) 1.30
Central analgesic effect of acetaminophen but not of aspirin. Clin Pharmacol Ther (1991) 1.30
Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res (1998) 1.29
Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett (1989) 1.25
Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther (1989) 1.23
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J (2008) 1.23
Human microsomal xenobiotic epoxide hydrolase. Complementary DNA sequence, complementary DNA-directed expression in COS-1 cells, and chromosomal localization. J Biol Chem (1988) 1.22
Isolation and characterization of rough endoplasmic reticulum associated with mitochondria from normal rat liver. Biochim Biophys Acta (1981) 1.22
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Am J Hum Genet (1990) 1.21
[Pharmacokinetics of a new cephalosporin, cefoperazone]. Schweiz Med Wochenschr (1979) 1.20
Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA (1988) 1.20
Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet (1996) 1.18
Dangerous interaction between amiodarone and quinidine. Lancet (1982) 1.16
Chemically induced porphyria: increased microsomal heme turnover after treatment with allylisopropylacetamide. Science (1971) 1.16
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol (2010) 1.15
Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci (1993) 1.14
Degradation of hepatic haem to porphyrins and oxophlorins in rats treated with 2-allyl-2-isopropylacetamide. Biochem Soc Trans (1976) 1.14
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics (1991) 1.14
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica (1986) 1.14
Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest (1999) 1.14
Parenchymal cells from adult rat liver in nonproliferating monolayer culture. II. Ultrastructural studies. J Cell Biol (1973) 1.13
Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther (1991) 1.12
Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther (1985) 1.12
Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics (2001) 1.12
High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem (1987) 1.11
Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics (2001) 1.11
Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics (1992) 1.09
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Nucleotide sequence of rabbit NAT1 encoding monomorphic arylamine N-acetyltransferase. Nucleic Acids Res (1990) 1.07
Isolation of a subfraction of rough endoplasmic reticulum closely associated with mitochondria. Evidence for its role in cytochrome P450 synthesis. Exp Cell Res (1978) 1.06
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol (2010) 1.06
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol (1996) 1.05
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther (1999) 1.05
MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun (1987) 1.05
Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol (1991) 1.05
Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer (2000) 1.03
High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res (2000) 1.03
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther (1998) 1.03
Purification, cloning, and characterization of a second arylalkylamine N-acetyltransferase from Drosophila melanogaster. DNA Cell Biol (2000) 1.02
Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem (1985) 1.02
Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res (1989) 1.00
A conserved nuclear receptor consensus sequence (DR-4) mediates transcriptional activation of the chicken CYP2H1 gene by phenobarbital in a hepatoma cell line. J Biol Chem (2000) 1.00
Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics (1996) 1.00
Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry (1987) 0.99
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther (1995) 0.99
The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet (1982) 0.99
Lack of acetaminophen ceiling effect on R-III nociceptive flexion reflex. Eur J Clin Pharmacol (1998) 0.99
Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology (1983) 0.98
N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis (1993) 0.98
Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics (1997) 0.98
Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol (1988) 0.97